62 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
RDY Dr. Reddy's Laboratories Ltd $35.7 $5.93B N/A
Article Searches
Top-Ranked Sector ETFs & Stocks to Buy for 2019 http://www.zacks.com/stock/news/346758/top-ranked-sector-etfs-stocks-to-buy-for-2019?cid=CS-ZC-FT-346758 Jan 10, 2019 - Investors could be well served by ETFs and stocks from top-ranked sectors.
VIVUS (VVUS) Banks on New Drug Pancreaze, Qsymia Lacks Luster http://www.zacks.com/stock/news/345606/vivus-vvus-banks-on-new-drug-pancreaze-qsymia-lacks-luster?cid=CS-ZC-FT-345606 Jan 03, 2019 - Although VIVUS (VVUS) is struggling with its legacy products, promotional initiatives and addition of cash-flow positive assets bode well for the company.
Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar http://www.zacks.com/stock/news/345603/teva-teva-ends-dispute-with-amgen-over-generic-sensipar?cid=CS-ZC-FT-345603 Jan 03, 2019 - Teva (TEVA) ends an ongoing patent dispute with Amgen over generic Sensipar by making an undisclosed payment.
Generic Industry on Path to Recovery: 3 Hot Picks for 2019 http://www.zacks.com/stock/news/345019/generic-industry-on-path-to-recovery-3-hot-picks-for-2019?cid=CS-ZC-FT-345019 Dec 28, 2018 - The stability in the industry sets the stage for players to get back on growth track. Here we discuss three stocks picks from the industry.
J&J Gets Positive CHMP Opinion for Prostate Cancer Treatment http://www.zacks.com/stock/news/338281/jj-gets-positive-chmp-opinion-for-prostate-cancer-treatment?cid=CS-ZC-FT-338281 Nov 19, 2018 - Johnson & Johnson's (J&J) apalutamide gets positive CHMP opinion for the treatment of adult patients with non-metastatic castration-resistant prostate cancer.
IMF Predicts Strong GDP Growth for India: Stocks in Focus http://www.zacks.com/stock/news/326912/imf-predicts-strong-gdp-growth-for-india-stocks-in-focus?cid=CS-ZC-FT-326912 Oct 09, 2018 - Strong growth in the Indian economy should aid stocks from this region.
Dr. Reddy's Sells Antibiotic Production Hub to UAE Drugmaker http://www.zacks.com/stock/news/325877/dr-reddys-sells-antibiotic-production-hub-to-uae-drugmaker?cid=CS-ZC-FT-325877 Oct 02, 2018 - Dr. Reddy's (RDY) divests its Bristol, TN-based antibiotic manufacturing site and related assets to an Abu Dhabi-based company.
Celgene's CEO Wants to Make the Biotech's Best-Selling Drug Obsolete -- Here's Why That's Great for Investors https://www.fool.com/investing/2018/09/07/celgenes-ceo-wants-to-make-the-biotechs-best-selli.aspx?source=iedfolrf0000001 Sep 07, 2018 - Revlimid is Celgene's biggest moneymaker by far. But here's how and why CEO Mark Alles wants to make it disappear.
Is First Trust BICK Index Fund (BICK) a Hot ETF Right Now? http://www.zacks.com/stock/news/313109/is-first-trust-bick-index-fund-bick-a-hot-etf-right-now?cid=CS-ZC-FT-313109 Jul 25, 2018 - Smart Beta ETF report for BICK
Dr. Reddy's Laboratories Limited (RDY) CEO G.V. Prasad on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4176612-dr-reddys-laboratories-limited-rdy-ceo-g-v-prasad-q4-2018-results-earnings-call-transcript?source=feed_tag_india May 23, 2018 - Dr. Reddy's Laboratories Limited (NYSE:RDY) Q4 2018 Earnings Conference Call May 22, 2018 09:00 AM ET Executives Saunak Savla - Investor Relations G.V. Prasad - Chief Executive Officer Erez Israeli -

Pages: 1234567

<Page 2>